Kevin Litchfield, PhD, University College London, London, UK, explains research into immune signatures in the tumor microenvironment. The immune signatures were divided into four categories: sources of antigen, drivers of immunescape, patterns of immune infiltration and signalling, and host factors. A systematic review was carried out and over 50 biomarkers were measured in a meta-analysis, in order to investigate the most important drivers of response to immunotherapy. The number of mutations, particularly clonal tumor mutational burden, was found to be critical for immunotherapy response, along with expression of key chemokines, including CXCL9 and CXCL13. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
